Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.74 |
| ▸ | SLC6A7 | Q99884 | 17/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.72 |
| ▸ | TSHR | P16473 | 1/20 | 0.72 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.68 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9999686 | 0.85 | KDM4E (0.68) | L3MBTL1SLC6A7ALDH1A1TSHRKDM4E | |
| SCHEMBL13149359 | 0.85 | SLC6A7 (0.92) | L3MBTL1SLC6A7ALDH1A1TSHRKDM4E | |
| SCHEMBL95079 | 0.85 | L3MBTL1 (0.74) | L3MBTL1SLC6A7ALDH1A1TSHRKDM4E | |
| SCHEMBL17378234 | 0.82 | NAMPT (0.69) | L3MBTL1SLC6A7ALDH1A1TSHRKDM4E | |
| SCHEMBL20261717 | 0.82 | CA12 (0.73) | ALDH1A1KDM4E | |
| SCHEMBL13149347 | 0.81 | SLC6A7 (0.92) | L3MBTL1SLC6A7ALDH1A1TSHRKDM4E | |
| SCHEMBL13149314 | 0.81 | SLC6A7 (0.92) | L3MBTL1SLC6A7ALDH1A1TSHRKDM4E | |
| SCHEMBL13149365 | 0.81 | SLC6A7 (0.70) | L3MBTL1SLC6A7ALDH1A1TSHRKDM4E | |
| SCHEMBL3583123 | 0.81 | SLC6A7 (1.00) | L3MBTL1SLC6A7ALDH1A1TSHRSLC6A3 | |
| SCHEMBL3585264 | 0.81 | SLC6A7 (1.00) | L3MBTL1SLC6A7ALDH1A1TSHRKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180079730-A1 | ANTI-PCSK9 COMPOUNDS AND METHODS FOR THE TREATMENT AND/OR PREVENTION OF CARDIOVASCULAR DISEASES | SHIFA BIOMEDICAL CORP (US) | 2018-03-22 | — | — | US | disclosed |
| US-20150376139-A1 | ANTI-PCSK9 COMPOUNDS AND METHODS FOR THE TREATMENT AND/OR PREVENTION OF CARDIOVASCULAR DISEASES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-12-31 | — | — | US | disclosed |
| US-8088774-B2 | Anti-inflammatory and protein kinase inhibitor compositions and related methods for downregulation of detrimental cellular responses and inhibition of cell death | NORTHWESTERN UNIVERSITY (US) | 2012-01-03 | — | — | US | disclosed |
| US-7888357-B2 | Anti-inflammatory and protein kinase inhibitor compositions and related methods for downregulation of detrimental cellular responses and inhibition of cell death | NORTHWESTERN UNIVERSITY (US) | 2011-02-15 | — | — | US | disclosed |
| EP-2264014-A1 | Substituted pyridazines as anti-inflammatory agents and protein kinase inhibitors | Université Louis Pasteur (FR) | 2010-12-22 | — | — | EP | disclosed |
| US-20100317665-A1 | Anti-Inflammatory And Protein Kinase Inhibitor Compositions And Related Methods For Downregulation Of Detrimental Cellular Responses And Inhibition Of Cell Death | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-12-16 | — | — | US | disclosed |
| US-20060073472-A1 | Anti-inflammatory and protein kinase inhibitor compositions and related methods for downregulation of detrimental cellular responses and inhibition of cell death | UNIVERSITE DE STRASBOURG (FR) | 2006-04-06 | — | — | US | disclosed |
| EP-1430033-A4 | ANTI-INFLAMMATORY AND PROTEIN KINASE INHIBITOR COMPOSITION AND METHOD OF USE | UNIV NORTHWESTERN (US) | 2004-12-15 | — | — | EP | disclosed |
| EP-1430033-A1 | ANTI-INFLAMMATORY AND PROTEIN KINASE INHIBITOR COMPOSITION AND METHOD OF USE | NORTHWESTERN UNIVERSITY (US) | 2004-06-23 | — | — | EP | disclosed |
| US-20030176437-A1 | Anti-inflammatory and protein kinase inhibitor compositions and related methods for downregulation of detrimental cellular responses and inhibition of cell death | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2003-09-18 | — | — | US | disclosed |
| WO-2003018563-A1 | ANTI-INFLAMMATORY AND PROTEIN KINASE INHIBITOR COMPOSITION AND METHOD OF USE | NORTHWESTERN UNIVERSITY (US) | 2003-03-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180079730-A1 | ANTI-PCSK9 COMPOUNDS AND METHODS FOR THE TREATMENT AND/OR PREVENTION OF CARDIOVASCULAR DISEASES | PCSK9, PCSK7, PCSK6 | L3MBTL1 2242/4885SLC6A7 4396/4885ALDH1A1 4302/4885 |
| US-20150376139-A1 | ANTI-PCSK9 COMPOUNDS AND METHODS FOR THE TREATMENT AND/OR PREVENTION OF CARDIOVASCULAR DISEASES | PCSK9, PCSK7, PCSK6 | L3MBTL1 2242/4885SLC6A7 4396/4885ALDH1A1 4302/4885 |
| US-20060073472-A1 | Anti-inflammatory and protein kinase inhibitor compositions and related methods for downregulation of detrimental cellular responses and inhibition of cell death | CASP2, CASP1, DAPK2 | L3MBTL1 1685/4885SLC6A7 4596/4885ALDH1A1 4515/4885 |
| US-20030176437-A1 | Anti-inflammatory and protein kinase inhibitor compositions and related methods for downregulation of detrimental cellular responses and inhibition of cell death | CASP2, CASP1, DAPK2 | L3MBTL1 1685/4885SLC6A7 4596/4885ALDH1A1 4515/4885 |
| US-20100317665-A1 | Anti-Inflammatory And Protein Kinase Inhibitor Compositions And Related Methods For Downregulation Of Detrimental Cellular Responses And Inhibition Of Cell Death | CASP2, CASP1, DAPK2 | L3MBTL1 1685/4885SLC6A7 4596/4885ALDH1A1 4515/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.